3 results
Approved WMOCompleted
To determine the safety and tolerability of L19-IL2 combined with SABR.
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Approved WMOCompleted
Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma